ENG | SWE
History
2011
- LinkMed AB changes name to Allenex AB
- Anders Karlsson becomes new CEO of LinkMed and replaces Ingemar Lagerlöf
- LinkMed acquires Olerup Inc., which becomes part of the Group
2010
- In the fourth quarter, LinkMed changed classification on NASDAQ OMX to Life Sciences Tools & Services
- Organizational changes were implemented by LinkMed in the fourth quarter as a result of the company’s new strategic focus.
- In the third quarter, LinkMed announced the company’s shift in strategy to fully focus on its transplantation sector companies
- LinkMed acquires NorDiag’s part of Olerup GmbH and Olerup GmbH becomes a part of the LinkMed Group
2009
- ONCOlog Medical is given FDA clearance to market and sell the PatLog® system in the U.S.
- LinkMed carried out a SEK 91.3 million rights issue
- Olerup International is established and acquires the distribution rights for Olerup SSP’s products from Qiagen
- GmbH, while also gaining the Norwegian biotech company NorDiag as a partner
- Likvor’s CELDA™ product is CE marked.
- Olerup SSP’s HLA typing kits receive clearance from the FDA in the U.S. and the Canadian Health Canada
- LinkMed implements a rights issue of convertible bonds at a value of SEK 84.8 million
- LinkMed acquires a further 50.8 percent of AbSorber, which thereby is included in the group as a subsidiary
- LinkMed has a total of eleven portfolio companies and two wholly-owned subsidiaries
2008
- LinkMed acquires Olerup SSP
- AbSorber receives FDA clearance for XM-ONE®
- OrtoWay’s product OrtoWell™ is CE marked and in clinical use
- LinkMed has a total of 12 portfolio companies and one wholly-owned subsidiary
2007
- LinkMed has a total of 10 portfolio companies
- Pharmacolog is formed through a spin off from ONCOlog Medical
- Likvor – new portfolio company
2006
- Ortoviva (later renamed OrtoWay) – new portfolio company
- Streamlining completed with sale of Pegasus lab
- Monica Caneman appointed as chairman of the Board
- Ingemar Lagerlöf returns to position of CEO
- Company is listed on the Stockholm Stock Exchange and an IPO of SEK 210.0 million is conducted
2005
- NovaHep – new portfolio company
2004
- ONCOlog Medical – new portfolio company
- Streamlining of the company continues with the divestment of NDA Regulatory Services
2003
- Recopharma is spun off from AbSorber to develop therapies based on recombinant glycoproteins, while AbSorber focuses on the transplantation field. LinkMed remains part owner of both companies
2002
- SACS Medical and Biovator – new portfolio companies
2001
- IMED – new portfolio company
- New CEO appointed, Ingemar Lagerlöf shifts focus to primarily concentrate on portfolio companies
2000
- AbSorber, Pegasus lab, BioResonator and Synergica – new portfolio companies
1999
- NDA Regulatory Services and Sygn Software – new portfolio company
1998
- LinkMed is founded by LinkTech AB and Ingemar Lagerlöf to invest in early stage life science sector
- AnaMar – first portfolio company
- Ingemar Lagerlöf is appointed CEO of the company and Gunnar Mattsson Chairman of the Board